drugset / Trial / NCT02237638
Phase I Study on VEGF Vaccination in Metastatic Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The primary objectives of this study are to investigate the safety and tolerability profile of the therapeutic vaccine hVEGF26-104/RFASE and to determine the effective dose of hVEGF26-104/RFASE required to neutralize VEGF in serum, defined as a VEGF level below 9,0 pg/mL.
Timeline
- Start
- 2014-04
- Primary completion
- 2020-01
- Completion
- 2020-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RFASE | Other / unclassified | 20 mg/ml | Intramuscular |
| Subject | hVEGF26-104 | Vaccine | 62.5 ug/ml | Intramuscular |
| Subject | hVEGF26-104 | Vaccine | 125 ug/ml | Intramuscular |
| Subject | hVEGF26-104 | Vaccine | 250 ug/ml | Intramuscular |
| Subject | hVEGF26-104 | Vaccine | 500 ug/ml | Intramuscular |